



Original article

Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors



Tamás Kálai^a, Robin Altman^b, Izumi Maezawa^c, Mária Balog^a, Christophe Morisseau^d, Jitka Petrlova^b, Bruce D. Hammock^d, Lee-Way Jin^c, James R. Trudell^e, John C. Voss^b, Kálmán Hideg^{a,*}

^a Institute of Organic and Medicinal Chemistry, University of Pécs, H-7624 Pécs, Szegedi St. 12. Pécs, Hungary

^b Department of Biochemistry & Molecular Medicine, University of California Davis, Davis, CA 95616, USA

^c M.I.N.D. Institute and Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA

^d Department of Entomology and UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA

^e Department of Anesthesia, Beckman Program for Molecular and Genetic Medicine, Stanford University, Stanford, CA 94305-5117, USA

ARTICLE INFO

Article history:

Received 7 August 2013

Received in revised form

3 March 2014

Accepted 8 March 2014

Available online 12 March 2014

Keywords:

Alzheimer's disease

Antioxidants

Nitroxides

Spin trapping

Tacrine

ABSTRACT

A series of new Tacrine analogs modified with nitroxides or pre-nitroxides on 9-amino group via methylene or piperazine spacers were synthesized; the nitroxide or its precursors were incorporated into the Tacrine scaffold. The new compounds were tested for their hydroxyl radical and peroxyl radical scavenging ability, acetylcholinesterase inhibitor activity and protection against A β -induced cytotoxicity. Based on these assays, we conclude that Tacrine analogs connected to five and six-membered nitroxides via piperazine spacers (**9b**, **9b/HCl** and **12**) exhibited the best activity, providing direction for further development of additional candidates with dual functionality (anti Alzheimer's and antioxidant).

© 2014 Elsevier Masson SAS. All rights reserved.

1. Introduction

Alzheimer's disease (AD) is an age-related neurodegenerative process that gradually worsens over time. Many clinical symptoms are associated with AD including memory loss, disorientation, language impairment, etc. The etiology of AD has not been elucidated yet, several factors such as amyloid- β (A β) deposits [1], τ -protein aggregation, oxidative stress [2], and decreased acetylcholine levels [3] play significant role in the pathology of disease [4]. Currently no treatment is available to cure AD and clinical treatments have only palliative effects. Such treatments include acetylcholinesterase inhibitors (AChEIs) (Tacrine, donepezil, rivastigmine, galantamine) restoring cholinergic deficit, and the NMDA receptor antagonist (memantine) limiting glutamate excitotoxicity. In spite of research efforts, drugs that can reverse or halt the pathology of AD are still lacking. Because of the complexity of AD, a new approach has been proposed for addressing the disease: simultaneous targeting of the multiple pathological processes

involved in the neurodegenerative cascade [5]. The approach involves the combination of therapeutic agents that act independently on different etiological targets. This strategy has proven to be successful in treatment of similarly complex diseases such as HIV, cancer and hypertension. In the case of AD, a combination of AChEIs with compounds targeting other pathogenic factors might offer several benefits, at least in the improvement of clinical symptoms of this disease. Several innovative strategies have been published recently, which produced enhanced therapeutic effects over AChEI monotherapy [6].

In the light of this, Tacrine, an AChEI, has been combined with carvedilol [7], melatonin [8], and ferulic acid derivatives [9]. We have recently published the structure of spin-labeled fluorene (SLF), containing a pyrroline nitroxide group that provides both increased cell protection against toxicity of A β oligomers (A β O) and a route to directly observe the binding of the fluorene to the A β O assembly by EPR spectroscopy [10]. Among the fluorene derivatives, the pyrroline nitroxide ring-containing derivatives were found especially useful in counteracting A β peptide toxicity, as they possess both antioxidant properties and the ability to disrupt A β O species [10].

* Corresponding author.

E-mail address: kalman.hideg@aok.pte.hu (K. Hideg).


Nitroxides are stable free radicals that rapidly cross cell-membranes, preempt free-radical formation by oxidizing redox-active metal ions (equation (1), Fig. 1), and function both as intra- and extracellular SOD mimics (equations (2) and (3)). The reduced form of the nitroxide, hydroxylamine, also has antioxidant activity; a proton and electron donor species (equation (4)). The sterically hindered amine (pre-nitroxide) with ROS scavenging offers a non-toxic stable nitroxide free radical (equation (5)). Several studies indicate that modification of cardioprotective agents [11], PARP-inhibitors [12], or neuroprotective ebselen [13] with nitroxides has a beneficial influence on their activity, being supplemented by the nitroxide's "in status nascent acting" antioxidants and radical scavengers.

With these concepts in mind, we focused our attention to combine nitroxide and/or nitroxide precursors with 9-amino-1,2,3,4-tetrahydroacridine (Tacrine **1b**) in the hope that nitroxides or their precursors (amines and hydroxylamines) may emerge as building blocks in the search of new dual active compounds to confront AD, a disease where oxidative stress contributes significantly to the pathogenesis. In this paper, we report the synthesis and biological study of these Tacrine–nitroxide hybrids by modifying the amino group of Tacrine or by incorporating the nitroxide moiety into the Tacrine scaffold via a substitution of the saturated ring (Scheme 1).

2. Results and discussion

2.1. Chemistry

In order to alkylate the amino-group of Tacrine (**1b**) [14] it was condensed with aldehydes **2** [15] and **3** [16] in toluene in the presence of piperidine to result in a Schiff-base, which was reduced with lithium aluminum hydride in THF to offer compounds **4b** and **5** (Scheme 1). Treatment of 9-chloro-1,2,3,4-tetrahydroacridine **6** [17] with five equivalents of piperazine in refluxing pentanol offered compound **7**, a key intermediate, which could be alkylated easily on secondary amine with a paramagnetic allylic bromide **8** [18] to offer compound **9b**. Alkylation of **7** with propargyl bromide gave compound **10** which was conjugated with the paramagnetic



Scheme 1. (a) toluene, piperidine (0.01 equiv.), reflux, 24 h, then work-up, LiAlH₄, THF, 2 h, 0 °C → rt., 22–40%.

azide **11** [19] in Cu(I) catalyzed 1,3-dipolar cycloaddition reaction in DMSO [20] to yield **12**, the triazol spacer containing compound. Alkylation of compound **7** with 2,3,4-trimethoxybenzylchloride afforded compound **13**, which combines an anti-ischemic metabolic agent, trimetazidine [21] and the AChEI Tacrine (Scheme 2).

Reaction of **14** (2-aminobenzonitrile) with **15** (triacetonamine) in the presence of 2.5 equiv aluminum-chloride in dichloroethane [14,22] at reflux temperature after work-up gave compound **16b** which could be oxidized with H₂O₂ in the presence of Na₂WO₄ to yield nitroxide **17b**. Reaction of 4-oxo-TEMPO with 2-aminobenzonitrile in the presence of Lewis acid, despite the consumption of starting materials, did not give compound **17b**. For the synthesis of further Tacrine analogs **19b**, **20b**, **22b** and **24b** several diamagnetic ketones **18** [23], **21**, **23** were incorporated into the Tacrine scaffold under the same conditions used in the synthesis of compound **16b**. From these compounds **19b** could be oxidized to **20b** nitroxide with H₂O₂ in the presence of Na₂WO₄. (Scheme 3) To achieve better solubility both amines and nitroxides were converted to HCl salts by treatment with HCl saturated ethanol [24] indicated as **1/HCl**, **4/HCl**, **9/HCl**, **16/HCl**, **17HCl**, **20/HCl**, **22/HCl**, **24/HCl**. In the case of nitroxides, this resulted in hydroxylamine formation.






Fig. 1. Possible radical scavenging mechanisms and transformations of nitroxides and pre-nitroxides.



Scheme 2. (a) pentanol, piperazine (5.0 equiv.), 140 °C, 12 h, 58%; (b) **8** (1.1 equiv.), CHCl₃, K₂CO₃ (1.1 equiv.) reflux, 3 h, 62%; (c) propargyl bromide (1.1 equiv.), CHCl₃, K₂CO₃ (1.1 equiv.) reflux, 3 h, 78%; (d) DMSO, CuI (0.3 equiv.), 40 °C, 4 h, 62%; (e) 2,3,4-trimethoxybenzylchloride, CHCl₃, K₂CO₃ (1.1 equiv.) reflux, 3 h, 55%.



Scheme 3. (a) 1,2-dichloroethane, AlCl₃ (2.5 equiv.) reflux, 2–3 h, 32–52%; (b) EtOH, aq. 30% H₂O₂, Na₂WO₄·2H₂O (0.1 equiv.), rt., 10 h, 22–39%.

2.2. Cholinesterase inhibitory activity and Aβ-induced cytotoxicity protection

In designing new Tacrine derivatives, nitroxide as an antioxidant building block was bound to amino functional group with the short methylene spacers as for compounds **4b**, **4/HCl**, **5** and compounds with longer spacers such as compounds **9b**, **9/HCl** and **12**. To demonstrate the importance of the nitroxide moiety or its precursor diamagnetic compounds **7**, **10**, **13** also were tested. The other possibility was the incorporation the pyrroline- or tetrahydropyridine nitroxide ring into the Tacrine scaffold. We synthesized compounds **16b**, **17b**, **19b**, **20b**, **22b** and **24b** with modified Friedlander synthesis. All the new Tacrine analogs were tested on hydroxyl radical scavenging activity, peroxy radical scavenging activity, acetylcholinesterase (from bovine erythrocyte) inhibitory activity, and Aβ-caused cell death inhibitory activity. The ROS scavenging activity and AChEI activity correlation with Aβ-induced cytotoxicity was investigated to find compounds with best antioxidant and anti Alzheimer's activity. As in AD, the memory dysfunction is a consequence of the cholinergic disturbances in the afflicted areas, AChE inhibitors are used to limit the amount of acetylcholine in the brain. In consequence, those cells which are still alive and produce acetylcholine may restore the cholinergic deficit at synaptic sites. For testing Tacrine analogs it was essential to determine AChE inhibitory activity of the new derivatives. Tacrine (**1b**) and its hydrochloride salt (**1/HCl**) have only acetylcholinesterase activity and do not exhibit any protection against Aβ-induced cytotoxicity. Compounds **4b**, **4/HCl**, **5**, **9b**, **9/HCl**, **10** and **12** exhibit less AChEI activity than compound **1b**, but their protective concentrations against Aβ-induced cytotoxicity are below 20 μM. While compounds **13**, **16b**, **16/HCl**, **17b**, **17/HCl**, **19b**, **19/HCl**, **20b**, **20/HCl**, **22b**, **22/HCl**, **24b** and **24/HCl** also exhibit notable protective activity against the induced cytotoxicity, their AChEI activity is practically lost (over 40 μM), only compounds **24** and **24/HCl** produced limited AChEI activity. Hence it can be concluded that beyond compound **13**, all the other ineffective analogs contain heterocyclic (pyrroline or tetrahydropyridine) ring incorporated into the Tacrine scaffold, e.g., condensed with a quinoline moiety (Fig. 2.). To understand the difference in AChEI activity of compounds **12**, **13** and **16b** docking studies were performed.

2.3. Docking of Tacrine derivatives to acetylcholinesterase

A goal of the docking studies was to understand why compound **16b** is inactive while compound **12** is active in experimental studies. Fig. 3a and b show a zoomed-in view of the ligands docked




Fig. 2. Inhibitory and cell protection activities of Tacrine derivatives. The concentration of compound resulting in 50% inhibition (IC₅₀) of bovine acetylcholinesterase is represented by black bars. Bars with arrows represent IC₅₀ values exceeding 40 μM. Protection against Aβ-induced cytotoxicity in MC65 cells is reported by the concentration of compound that provides 50% protection (PC₅₀, red bars). Light red bars represent compounds that offered no significant protection. Error bars represent the standard error of the mean from three independent measurements. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

into the binding site of acetylcholinesterase. We used a module of Discovery studio 3.5 (DS3.5, Accelrys Inc., San Diego, CA) to search for inter-molecular H-bonds as well as π-bonds. Fig. 3a shows that **16b** fits nicely into the binding site, but generates only one π-bond from N25 to Tyr334 of 2CKM. In contrast, compound **12** provided one H-bond between Tyr121 on N25. Moreover, it also made four π-bonds; one from the ring containing C4 to Trp279, one from N36 to Phe330, and two from N36 to each ring of Trp84. When the total energies after the final minimization were compared, compound **16b** was −28716.9 versus compound **12** of −28842.9 kcal/mol; a difference of 126 kcal/mol. It is likely that the large difference in




Fig. 3. a. Zoomed-in view of compound **16b** docked into the binding site of acetylcholinesterase. b. Zoomed-in view of compound **12** docked into the binding site of acetylcholinesterase.

interaction energies between compound **12** and **16b** accounts for the lack of activity of compound **16b**. The latter molecule provided only one π -bond to the receptor whereas compound **12** provided one H-bond and four π -bonds. We did not calculate the more distributed van der Waals interactions, but they likely also added to the increased interaction energy of the larger compound **12**. Docking experiments showed that both Tacrine (**1b**) and compound **13** are bound equally well and the differences in efficacy at the binding site were not apparent. However, compound **13** structurally more similar to ditacrine (two rigid 1,2,3,4-tetrahydroacridine unit connected with a heptan-1,7-diamine flexible spacer) and the binding energy of compound **13** is somehow less than that of ditacrine (see table in the [supplementary information](#)).

2.4. ROS scavenging activity

To study the ROS scavenging activity of the Tacrine analogs, the signal intensity of the BMPO spin trap [25] was measured by EPR spectroscopy following induction of either hydroxyl or superoxide radicals. BMPO produces a distinct EPR line shape, depending on whether the adduct is formed with the hydroxyl or superoxide radical (Fig. 4). Fig. 4 illustrates how Tacrine derivatives with appreciable scavenging activity compete for ROS species (e.g., compound **13**), thereby producing a reduced BMPO EPR line intensity. This compares to compound **1b**, which has no significant effect on the level of radical detected (Fig. 4). In comparison of the hydroxyl radical scavenging activity and the protective effect against A β -induced cytotoxicity, the results are more or less parallel suggesting that free radical processes have a contribution in the induced cytotoxicity. Compounds without nitroxide or nitroxide precursors (**1b**, **1/HCl**, **7**, **10**) have limited $\cdot\text{OH}$ and superoxide scavenging activity, while compounds **4b**, **4/HCl**, **5**, **9b**, **9/HCl**, **12**




Fig. 5. Hydroxyl (black) and peroxy (red) radical scavenging compared to the cell protection activities of Tacrine derivatives. The bars represent a qualitative determination of scavenging by measuring the residual amplitude of the third BMPO resonance line in the presence of the indicated compound at 1 mM, with 100% representing no identifiable scavenging activity. Error bars represent the fractional error determined from the signal: noise of each experiment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

provide remarkable ROS scavenging activity and protection against A β -induced cytotoxicity (Figs. 2 and 5). The exception is the diamagnetic trimetazidine derivative (**13**), a compound with notable antioxidant activity [26]. Regarding the anellated derivatives, sterically hindered amines (**16b**, **16/HCl**, **19b**, **19/HCl**)




Fig. 4. EPR spectra of hydroxyl or superoxide adducts to the BMPO spin trap in the presence of compounds **1b** or **13**. Final BMPO concentration in the reaction mixture was 10 mM, and the tacrines were at 1 mM.




Fig. 6. Correlation between ROS scavenging and cell protection activities for Tacrine compounds. Shown for the indicated Tacrines is the index of cell protection (PC₅₀) plotted according to its percent BMPO spin trap signal. Compounds **1b**, **7** and **10** are not included because they do not provide any significant level of cell protection.

provide a lower protective activity compared to nitroxides **17b** and **20b** and their hydroxylamine salt (**17/HCl** and **20/HCl**). Furthermore, the annulated six membered nitroxide (**17b**) provides superior $\cdot\text{OH}$ scavenging activity compared to the five-membered annulated nitroxide (**20b**). While several factors may influence the thermodynamics and kinetics of these reactions, a general determining factor is the flexibility of the nitrogen center to planarize upon oxidation or pyramidalize upon reduction [27]. Thus, monocyclic nitroxides (**4b**, **5**, **9b**, **12**) readily take part in redox processes, as does the six-membered nitroxide with the tetrahydroisoquinoline scaffold (**17b**). However, in the case of the five-membered rings condensed into an aromatic system (**19**, **20**), the severely constricted ring impairs reactivity at the nitrogen.

As expected, diamagnetic derivatives (**1b**, **7**, **10**, **13**, **16b**, **16/HCl**, **20b**, **20/HCl**, **22b**, **22/HCl**, **24b**, **24/HCl**) lack peroxy radical scavenging activity, while the nitroxide or hydroxylamine containing compounds (**4b**, **4/HCl**, **5**, **9b**, **9/HCl**, **12**, **17b**, **17/HCl**, **20b**, **20/HCl**) are excellent in this regard. We can also note that paramagnetic Tacrines produce better performance in peroxide scavenging than in $\text{HO}\cdot$ scavenging (Fig. 5). It is well known that $\text{A}\beta$ toxicity is related to its redox properties [28] and contributes to oxidative damage by inducing lipid peroxidation, which in turn generates additional cytosolic free radical formation, leading to mitochondrial and cytoskeletal compromise, depletion of ATP, and ultimate apoptosis. Our findings that nitroxide or its precursor containing Tacrine analogs (**4b**, **4/HCl**, **5**, **9**, **12**, **17b**, **17/HCl**, **20b**, **20/HCl**) with free radical scavenging capabilities (Fig. 1) corroborate the findings that compounds with antioxidant activity (folate, vitamin E, acetyl-L-carnitine, ferulic acid ethyl ester) provide protection against $\text{A}\beta$ -induced toxicity [29,30].

3. Conclusions

A new series of tacrine-nitroxide and nitroxide precursor hybrid related derivatives were synthesized as dual acetylcholinesterase inhibitors and antioxidants (radical scavengers). Our synthesis varied the nitroxide position, tethered to a 9-amino group or annulated to the Tacrine pyridine ring. The influence of the nitroxide ring size was also explored. Compounds were tested on hydroxyl radical scavenging, peroxy radical scavenging, $\text{A}\beta$ -induced cell death and AChE inhibitory assays. The general correlation between ROS scavenging capability and protection against $\text{A}\beta$ toxicity is illustrated in Fig. 6. The correlation with hydroxyl scavenging appears a little stronger. It should be noted the solvent and potential carrier components are significantly different in the cell protection

assay (e.g., the presence of lipids and proteins). Thus differences in compound solubility (in all assays) or uptake (in the cell protection assay) is likely to produce divergence between the measurements. Such factors are apparent for the dissimilar performance of the base and acid species. Compounds **9** and **12** were the most efficient AChE inhibitors and radical scavengers and exhibited remarkable cell protection toward $\text{A}\beta$ -induced toxicity, although compounds **4**, **5**, **17** and **20** also exhibited notable activity (Fig. 6). This dual protective (AChE inhibitory and antioxidant) profile of compounds **9** and **12** makes these compounds promising leads for developing disease modifying drugs for the future treatment of AD.

4. Experimental protocols

4.1. Chemistry

Melting points were determined with a Boettius micro melting point apparatus and are uncorrected. Elemental analyses (C, H, N, S) were performed on Fisons EA 1110 CHNS elemental analyzer. Mass spectra were recorded on a Thermoquest Automass Multi and VG TRIO-2 instruments and in the EI mode. ^1H NMR spectra were recorded with Varian UNITYINOVA 400 WB spectrometer and Bruker Avance 3 Ascend 500. Chemical shifts are referenced to Me_4Si . Measurements were run at 298 K probe temperature in CDCl_3 solution. ESR spectra were taken on Miniscope MS 200 in 10^{-4} M CHCl_3 solution and monoradicals gave triplet line. Flash column chromatography was performed on Merck Kieselgel 60 (0.040–0.063 mm). Qualitative TLC was carried out on commercially available plates ($20 \times 20 \times 0.02$ cm) coated with Merck Kieselgel GF₂₅₄. Triacetoneamine, 1,2,2,6,6-pentamethylpiperidone, 1-methyl piperidone, compound **14**, Tacrine and all other chemicals were purchased from Aldrich, compound **2** [15], **3** [16], **6** [17], **8** [18], **11** [19], **18** [23] were prepared as described earlier.

4.1.1. Synthesis of 9-amino substituted Tacrines

In a 250 mL round bottomed flask equipped with a Dean–Stark constant separator which is connected to a reflux condenser, a solution of Tacrine (**1**) (1.98 g, 10.0 mmol) and aldehyde **2** or **3** (10.0 mmol) and piperidine 85 mg (1.0 mmol) in toluene (100 mL) was heated on reflux temperature for 24 h. After cooling the solvent was evaporated off and the residue was purified by flash column chromatography to remove starting materials. To the solution of Schiff-base in dry THF (30 mL) under N_2 at 0°C LiAlH_4 (20.0 mmol, 8.3 mL) was added dropwise. After consumption of the Schiff-base (~ 2 h) the mixture was poured on mixture of ice and 10% aq. NaOH

solution (100 mL) and the mixture was stirred at room temperature for 30 min. The organic phase was separated, the aqueous phase was extracted with CH_2Cl_2 (2×20 mL). The combined organic phase was dried (MgSO_4), filtered and evaporated and the residue was purified by flash column chromatography (hexane–EtOAc, CHCl_3 –Et $_2\text{O}$) to yield the title compounds as yellow crystalline solid.

4.1.1.1. 2,2,5,5-Tetramethyl-3-[(1,2,3,4-tetrahydroacridin-9-yl)amino-methyl]-2,5-dihydro-1H-pyrrol-1-yloxy radical (4b) (HO-4219). 1.40 g (40%), mp 153–155 °C. Ms (EI) m/z (%): 350 (M^+ , 19), 305 (7), 277 (11), 211 (100), 197 (56). ^1H NMR of NOME derivative (CDCl_3) δ = 7.96–7.93 (m, 2H), 7.58 (t, 1H, J = 8 Hz), 7.38 (t, 1H, J = 8 Hz), 5.65 (s, 1H), 4.02 (s, 1H), 3.73 (s, 2H), 3.65 (s, 3H), 3.10 (br, 2H), 2.74 (br, 2H), 1.95 (br, 4H), 1.29 (s, 6H), 1.26 (s, 6H). Anal calcd. for: $\text{C}_{22}\text{H}_{28}\text{N}_3\text{O}$: C 75.39, H 8.05, N 11.99, found: C 75.15, H 7.97, N 11.86.

4.1.1.2. 2,2,6,6-Tetramethyl-4-[(1,2,3,4-tetrahydroacridin-9-yl)amino-methyl]-1,2,3,6-tetrahydropyridin-1-yloxy radical (5) (HO-4637). 800 mg (22%), mp 157–159 °C. Ms (EI) m/z (%): 364 (M^+ , 14), 334 (2), 278 (20), 211 (100), 197 (45). Anal calcd. for: $\text{C}_{23}\text{H}_{30}\text{N}_3\text{O}$: C 75.79; H, 8.30; N, 11.53, found: C 75.96, H 8.12, N 11.55.

4.1.2. 9-(Piperazin-1-yl)-1,2,3,4-tetrahydroacridine (7) (HO-4387)

In a sealed tube a stirred mixture of compound **6** (2.18 g, 10.0 mmol) and piperazine (4.30 g, 50.0 mmol) in pentanol (10 mL) were heated at 140 °C for 12 h. After cooling the mixture was diluted with water (20 mL) and extracted with CHCl_3 (2×20 mL). The organic phase was dried (MgSO_4), the drying agent was filtered off, solvents were evaporated and the residue was purified by flash column chromatography (CHCl_3 –Et $_2\text{O}$) to yield the title compound as an off-white solid 1.54 g, (58%), mp 156–158 °C. Ms (EI) m/z (%): 267 (M^+ , 9), 225 (23), 69(64) 57 (100). ^1H NMR of 2HCl salt (D_2O) δ = 8.17 (d, 1H), 7.92–7.91 (m, 2H), 7.74–7.71 (m, 1H), 3.87 (t, 4H, J = 5 Hz), 3.54 (t, 4H, J = 5 Hz), 3.22 (t, 2H, J = 6.0 Hz), 2.92 (t, 2H, J = 6 Hz), 1.95 (m, 2H), 1.86 (m, 2H). ^{13}C NMR (CD_3OD) δ = 160.9, 157.0, 138.2, 133.2, 127.9, 126.5, 125.5, 124.0, 119.5, 48.3, 43.81, 28.7, 26.2, 21.6, 20.2. Anal calcd. for: $\text{C}_{17}\text{H}_{21}\text{N}_3$: C, 76.37; H, 7.92; N, 15.72 found: C 76.21, H 7.82, N 15.63.

4.1.3. General procedure for alkylation of 9-(piperazin-1-yl)-1,2,3,4-tetrahydroacridines (9b, 10, 13)

A stirred solution of compound **7** (1.33 g, 5.0 mmol) and compound **8** (5.5 mmol) or propargyl bromide or 2,3,4-trimethoxybenzylchloride (5.5 mmol) and K_2CO_3 (760 mg, 5.5 mmol) in CHCl_3 (30 mL) was heated at reflux till the consumption of starting material (~ 3 h). After cooling the inorganic salt was filtered off, the organic phase washed with water (10 mL), the organic phase was separated, dried (MgSO_4), filtered and evaporated. The residue was purified by flash column chromatography (CHCl_3 –Et $_2\text{O}$) to furnish the title compounds.

4.1.3.1. 2,2,5,5-Tetramethyl-3-[4-(1,2,3,4-tetrahydroacridin-9-yl)piperazin-1-ylmethyl]-2,5-dihydro-1H-pyrrol-1-yloxy radical 9b (HO-4380). 130 mg (62%), yellow solid, mp: 138–140 °C. Ms (EI) m/z (%): 419 (M^+ , 43), 389 (5), 280 (75), 267 (82), 225 (100). Anal calcd. for: $\text{C}_{26}\text{H}_{35}\text{N}_4\text{O}$: C, 74.43; H, 8.41; N, 13.35 found: C 74.29, H 8.33, N 13.26.

4.1.3.2. 9-[4-(Prop-2-yn-1-yl)piperazin-1-yl]-1,2,3,4-tetrahydroacridine (10) (HO-4563). 119 mg (78%) yellow solid, mp. 94–96 °C. ^1H NMR (CD_3OD) δ = 8.17 (d, 1H, J = 9 Hz), 7.85 (d, 1H, J = 8 Hz), 7.60 (t, 1H, J = 7 Hz), 7.46 (t, 1H, J = 8 Hz), 3.44 (d, 2H, J = 2 Hz), 3.37 (t, 4H, J = 5 Hz), 3.06 (t, 2H, J = 7 Hz), 2.97 (t, 2H, J = 6.0 Hz), 2.81 (t, 3H, J = 5 Hz), 2.75 (s, 1H), 1.96 (m, 2H), 1.86 (m,

2H). ^{13}C NMR (CD_3OD) δ = 161.5, 155.1, 148.4, 129.9, 129.2, 128.4, 127.1, 126.4, 125.2, 79.1, 75.4, 53.9, 51.1, 47.8, 34.4, 27.8, 23.9, 23.6. Ms (EI) m/z (%): 305 (M^+ , 38), 266 (11), 209 (48), 67 (100). Anal calcd. for: $\text{C}_{20}\text{H}_{23}\text{N}_3$: C, 78.65; H, 7.59; N, 13.76; found: C 78.55, H 7.51, N 13.57.

4.1.3.3. 9-[4-(2,3,4-Trimethoxybenzyl)piperazin-1-yl]-1,2,3,4-tetrahydroacridine (13) (HO-4392). 127 mg (55%), yellow solid, mp 202–204 °C. ^1H NMR (2HCl salt in D_2O) δ = 8.14 (d, 1H, J = 8 Hz), 7.90 (s, 2H), 7.73 (t, 1H, J = 8 Hz), 7.28 (d, 1H, J = 8 Hz), 6.95 (d, 1H, J = 8 Hz), 4.46 (s, 2H), 3.98 (s, 3H), 3.88 (t, 4H, J = 5 Hz), 3.64 (m, 2H), 3.52 (m, 2H), 3.21 (t, 2H, J = 6.0 Hz), 2.90 (t, 2H, J = 6 Hz), 1.95 (m, 2H), 1.86 (m, 2H). ^{13}C NMR (CD_3OD): δ = 161.5, 155.2, 154.7, 154.0, 148.4, 143.5, 129.8, 129.0, 128.4, 127.2, 127.1, 126.3, 125.3, 124.2, 108.7, 61.8, 61.2, 57.8, 56.6, 55.1, 51.4, 34.4, 27.8, 23.9, 23.6. Ms (EI) m/z (%): 447 (M^+ , 12), 266 (90), 238 (44), 181 (100). Anal calcd. for: $\text{C}_{27}\text{H}_{33}\text{N}_3\text{O}_3$: C, 72.46; H, 7.43; N, 9.39; found: C 72.45, H 7.46, N 9.41.

4.1.4. Modification of the Tacrine analog by a nitroxide with click-reaction

2,2,6,6-Tetramethyl-4-[4-(1,2,3,4-tetrahydroacridin-9-yl)piperazin-1-ylmethyl]-1H-1,2,3-triazol-1-yl}piperidin-1-yloxy radical **10** (610 mg, 2.0 mmol) and compound **11** (394 mg, 2.0 mmol) in DMSO (5 mL) CuI (114 mg, 0.6 mmol) was added and the mixture was stirred under N_2 for 4 h at 40 °C. After consumption of the starting material the mixture was poured onto ice-water mixture (100 mL) and the precipitated solid was filtered and air-dried. The crude product was purified further by flash column chromatography (CHCl_3 –MeOH) to offer the title compound 657 mg (62%), beige solid, mp 152–154 °C. Ms (EI) m/z (%): 502 (M^+ , 8), 414(8), 267 (90), 250(100). Anal calcd. for: $\text{C}_{29}\text{H}_{40}\text{N}_7\text{O}$ C 69.29; H 8.02; N, 19.51, found: C 69.10, H 7.95, N 19.42.

4.1.5. Friedlander reaction for synthesis of 1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines and 1H-pyrrolo[3,4-b]quinoline general procedure (16b, 19b, 22b, 24b)

Mixture of cyclic ketone **15** or **18** or **21** or **23** (10.0 mmol) and 2-aminobenzonitrile (**14**) (1.18 g, 10.0 mmol) in 1,2-dichloroethane (30 mL) was stirred at room temperature for 10 min, then anhydrous AlCl_3 (3.32 g 25.0 mmol) was added in one portion and the mixture was stirred and refluxed for 2 h. After cooling the mixture was basified with 10% aq. NaOH (100 mL), the mixture was stirred at ambient temperature for 30 min. After separation of organic phase the aqueous phase was extracted with CH_2Cl_2 (2×20 mL). The combined organic phase was dried (MgSO_4), filtered and evaporated. The residue was purified by flash chromatography (hexane–EtOAc or CHCl_3 –Et $_2\text{O}$) to give the title compounds as solids in 32–52% yield.

4.1.5.1. 1,1,3,3-Tetramethyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-10-amine (16b) (HO-4276). 1.14 g, (45%), yellow solid, mp 141–143 °C. ^1H NMR (CD_3OD) δ = 7.96 (d, 1H, J = 8.5 Hz), 7.73 (d, 1H, J = 8.5 Hz), 7.57 (t, 1H, J = 7 Hz), 7.38 (t, 1H, J = 7 Hz), 2.87 (s, 2H), 1.69 (s, 6H), 1.24 (s, 6H). ^{13}C NMR (CD_3OD) 157.1, 148.8, 147.13, 130.3, 127.7, 125.2, 122.4, 120.0, 115.7, 53.7, 50.5, 48.1, 29.5, 29.3. Ms (EI) m/z (%): 255 (M^+ , 2), 240 (100), 223 (34), 43 (62). Anal calcd. for: $\text{C}_{16}\text{H}_{21}\text{N}_3$ C 75.26, H 8.29, N 16.46, found: C 75.40, H 8.12, N 16.32.

4.1.5.2. 1,1,3,3-Tetramethyl-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9-amine (19b) (HO-4278). 1.25 g, (52%), pale yellow solid, mp 152–154 °C. ^1H NMR (D_2O) δ = 8.13 (d, 1H, J = 8 Hz), 7.83 (t, 1H, 8 Hz), 7.76 (d, 1H, J = 8 Hz), 7.58 (t, 1H, J = 8 Hz), 1.92 (s, 6H), 1.89 (s, 6H). ^{13}C NMR (D_2O): 154.0, 153.2, 138.8, 134.5, 127.18, 122.7, 119.9, 116.4, 111.1, 68.2, 66.1, 25.71, 24.63. Ms (EI) m/z (%): 241 (M^+ , 2), 226 (100),

211 (25), 43 (18). Anal calcd. for: C₁₅H₁₉N₃ C 74.65, H 7.94, N 17.41, found: C 74.49, H 7.82, N 17.27.

4.1.5.3. 2-Methyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-10-amine (22b) (HO-4330). 1.00 g (32%), yellow solid, mp 213–215 °C. ¹H NMR (CDCl₃) δ = 8.55 (d, 1H, J = 8 Hz), 8.32 (bs, 1H), 7.96 (d, 1H), 7.81 (t, 1H, J = 8 Hz), 7.45 (t, 1H, J = 8 Hz), 3.51 (s, 2H), 3.10 (t, 2H, J = 6 Hz), 2.80 (t, 3H, J = 6 Hz), 2.50 (s, 2H). ¹³C NMR of 2 HCl salt (D₂O) δ = 151.1, 146.6, 137.5, 133.5, 126.6, 122.2, 119.8, 116.5, 101.1, 66.02, 58.4, 41.1, 30.4, 27.0, 22.8, 21.7, 20.0. Ms (EI) *m/z* (%): 313 (M⁺, 71), 212 (100), 196 (64), 170 (85). Anal calcd. for: C₁₃H₁₅N₃ C 73.21, H 7.09, N 19.70, found: C 73.15, H 7.03, N 19.55.

4.1.5.4. 1,1,2,3,3-Pentamethyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-10-amine (24b) (HO4330). 1.18 g (44%), brownish-yellow solid, mp 65–67 °C. ¹H NMR of 2 HCl salt (D₂O) δ = 7.96 (d, 1H, J = 8 Hz), 7.51 (t, 1H, J = 8 Hz), 7.39 (d, 1H, J = 8 Hz), 7.29 (1H, t, J = 8 Hz) 2.97 (s, 2H), 2.54 (s, 3H), 1.76 (s, 6H), 1.17 (s, 6H). ¹³C NMR of 2 HCl salt (D₂O) δ = 154.7, 145.6, 137.4, 134.5, 129.9, 122.5, 119.1, 114.9, 101.0, 49.6, 49.2, 43.1, 24.4. Ms (EI) *m/z* (%): 269 (M⁺, 4), 254 (100), 223 (39). Anal calcd. for: C₁₇H₂₃N₃ C 75.80; H 8.61; N 15.60, found: C 75.62, H 8.52, N 15.76.

4.1.6. Oxidation of compounds **16b** and **19b–17b** and **20b** nitroxide free radicals

To a stirred solution of amine **16b** or **19b** (5.0 mmol) and Na₂WO₄·2H₂O (164 mg, 0.5 mmol) in EtOH (20 mL) and water 5 (mL) 30% aq. H₂O₂ (5 mL) was added dropwise at 0 °C. After the addition the stirring was continued at room temperature and the course of the reaction was followed by TLC (hexane/EtOAc 2:1) and once by product (upon prolonged oxidation time pyridine-N-oxyl also formed) appears (~10 h) the organic solvent was evaporated and the mixture was extracted with CHCl₃ (2 × 30 mL). The organic phase was dried (MgSO₄) filtered and evaporated to offer the title nitroxides **17b** or **20b** as yellow solids.

4.1.6.1. 10-Amino-1,1,3,3-tetramethyl-3,4-dihydrobenzo[b][1,6]naphthyridin-2(1H)-yloxyl radical (17b) (HO-4277). 526 mg (39%), yellow solid, mp 179–181 °C. Ms (EI) *m/z* (%): 270 (M⁺, 21), 240 (18), 225 (100). Anal calcd. for C 71.08, H 7.46, N 15.54 found: 71.19, H 7.31, N 15.40.

4.1.6.2. 9-Amino-1,1,3,3-tetramethyl-1H-pyrrolo[3,4-b]quinolin-2(3H)-yloxyl radical (20b) (HO-4279). 281 mg (22%), yellow solid, mp > 230 °C. Ms (EI) *m/z* (%): 256 (M⁺, 62), 241 (45), 226 (77), 211 (100). Anal calcd. for C₁₅H₁₈N₃O C 71.08, H 7.46, N 15.54 found: C 71.96; H 7.56; N, 15.46.

4.2. Molecular modeling of compounds **12b** and **16b**

The structures of Tacrine, di-tacrine, compound **12b**, and compound **16b** were obtained. They were prepared for docking with the Generate Conformations module of Discovery Studio 3.5 (DS3.5, Accelrys Inc, San Diego, CA, USA). We considered two X-ray structures of acetylcholinesterase as the receptor for docking studies; a receptor with Tacrine docked (PDB ID 1ACJ) and one with di-tacrine docked (PDB ID 2CKM). We chose the latter structure as di-tacrine is closer in size and length to the planned ligands; compound **16b** (inactive in our assays) and compound **12b** (active in our assays). The acetylcholinesterase structure 2CKM was prepared for docking by adding hydrogens, checking for missing atoms, and assigning the CHARMM force field to all atoms. We used the CDocker module of DS3.5. CDocker uses a CHARMM-based molecular dynamics (MD) scheme to dock ligands into a receptor binding site. Random ligand conformations are generated using high-

temperature MD. The conformations are then translated into the binding site. Candidate poses are then created using random rigid-body rotations followed by simulated annealing. A final minimization with the CHARMM force field is then used to refine the ligand poses. We highlighted di-tacrine in the crystal structure of 2CKM and defined a sphere that contained it; approximately 11 Å. This sphere limited the possible positions of the ligands in subsequent docking runs. We used 1000 steps of molecular dynamics at 1000 K to produce ligand conformations for docking. After docking, we selected the ten top 'Hits' for refinement using molecular dynamics with simulated annealing. For each selected pose, we used 2000 steps of heating to a target temperature of 700 K and then 5000 steps of cooling to a target temperature of 300 K. Then we optimized each of the resulting poses to a gradient of 0.001 kcal/mol with DS3.5. We ranked the poses based on two criteria; CDocker energy and CDocker interaction energy. The latter value was the most informative, it is the difference between the total final energy of the docked complex and the sum of the energies of the receptor and the ligand. We chose the best complex of compound **16b** and compound **12b** based on the CDocker interaction energy value. For these two structures we performed an optimization of the entire receptor plus each ligand with a light restraining force of 10 kcal/(mol × Å).

4.3. Biological assays

4.3.1. Antioxidant activity assay

The free radical scavenging activity of the Tacrine compounds was determined by measuring the adduct levels accumulated by the spin trap BMPO (5-tert-butoxycarbonyl 5-methyl-1-pyrroline N-oxide, Applied Bioanalytical Labs, Bradenton, FL). Briefly, a mixture of horseradish peroxidase (100 ng), hydrogen peroxide (0.03%), and sodium azide (0.001%) in PBS pH 7.4 was used to generate superoxide radicals. Hydroxyl radicals were generated by mixing ferrous ammonium sulfonate (1 mg/mL) and hydrogen peroxide (0.03%) in PBS. Each of the superoxide or hydroxyl radical solutions also contained BMPO at a final concentration of 10 mM. After mixing the solution, an aliquot was immediately removed and combined with the tacrine (1 mM final concentration), and EPR measurements were obtained. The superoxide and hydroxyl radicals were measured as BMPO–OOH and BMPO–OH adducts, respectively. Electron paramagnetic resonance spectroscopy measurements of the BMPO spin traps were obtained at room temperature with a JEOL X-band spectrometer fitted with a loop-gap resonator. All spectra were recorded at room temperature and obtained by averaging two 2-min scans with a sweep width of 100 G at a microwave power of 3 mW and modulation amplitude optimized to the natural line width of the spin probe.

4.3.2. MTT cytotoxicity assay

The human neuroblastoma cell line (MC65) was used to determine the ability of the tacrine compounds to protect against Aβ oligomer-induced toxicity according to previously published protocols [31,32]. Briefly, the MC65 cell line conditionally expresses the carboxyl-terminal 99 residues of the Aβ precursor protein (APP-C99) in the absence of the transgene suppressor tetracycline (TC). Aβ is then generated from APP-C99 after cleavage by cellular γ-secretase. To generate Aβ, tetracycline was removed from the culture media, and as early as 4 h after TC removal Aβ oligomers began to accumulate intracellularly. Tacrine compounds were added immediately after TC removal and cells were maintained for 3 days without changing the media. Cytotoxicity was determined using the colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] assay.

4.3.3. Acetylcholinesterase inhibition assay

The acetylcholinesterase inhibitory activity of the tacrines was determined using acetyl-thio-choline and DTNB according to the method previously published by Wilson and Henderson [33]. Acetylcholinesterase from bovine erythrocytes was used in the assay at a final concentration of 80 µg/mL, and the buffer used for the measurements was 100 mM NaPO₄ (pH 8.0) containing 0.1 mg/mL BSA. Results are expressed as means ± standard deviation of at least three separate experiments.

Acknowledgments

This work was supported by grants from Hungarian National Research Fund OTKA K 81123 (KH), National Institutes of Health R01 AG029246 (JV), National Institutes of Health R01AA02098001A1 (JRT) and National Institutes of Health R01 ES002710 (BDH). The authors thank for Noémi Lazsányi for elemental analysis and Gergely Gulyás-Fekete (Dept of Biochemistry and Medicinal Chemistry, University of Pécs) for NMR measurements.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.ejmech.2014.03.026>.

References

- [1] M. Jucker, L.C. Walker, Pathogenic protein seeding in Alzheimer disease and other degenerative disorders, *Annals of Neurology* 70 (2011) 532–540.
- [2] R. Sultana, D.A. Butterfield, Role of oxidative stress in the progression of Alzheimer's disease, *Journal of Alzheimer's Disease* 19 (2010) 341–353.
- [3] M.S. Rafii, P.S. Aisen, Recent developments in Alzheimer's disease therapeutics, *BMC Medicine* 7 (2009) 7.
- [4] H.F. Kung, The β-Amyloid hypothesis in Alzheimer's disease: seeing is believing, *Medicinal Chemistry Letters* 3 (2012) 265–267.
- [5] G. Xiong, P.M. Doraiswamy, Combination drug therapy for Alzheimer's disease: what is evidence –based, and what is not? *Geriatrics* 60 (2005) 22–26.
- [6] M. Dumont, M.F. Beal, Neuroprotective strategies involving ROS in Alzheimer disease, *Free Radical Biology & Medicine* 51 (2011) 1014–1026.
- [7] M. Rosini, E. Simoni, M. Bartolini, A. Cavalli, L. Ceccarini, N. Pascu, D.W. McClymont, A. Tarozzi, M.L. Bolognesi, A. Minarin, V. Tumiatto, V. Andrisano, I.R. Mellor, C. Melchiorre, Inhibition of acetylcholinesterase, β-amyloid aggregation, and MND receptors in Alzheimer's disease: a promising direction for the multi-target-directed gold rush, *Journal of Medicinal Chemistry* 51 (2008) 4381–4384.
- [8] M.I. Rodríguez-Franco, M.I. Fernández-Bachiller, C. Pérez, B. Hernández-Ledesma, B. Bartolomé, Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties, *Journal of Medicinal Chemistry* 49 (2009) 459–462.
- [9] L. Fanga, B. Kraus, J. Lehmann, J. Heilmann, Y. Zhang, M. Decker, Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates, *Bioorganic & Medicinal Chemistry Letters* 18 (2008) 2905–2909.
- [10] T. Kálai, J. Petrlova, M. Balog, H.H. Aung, J.C. Voss, K. Hideg, Synthesis and study of 2-amino-7-bromofluorenes modified with nitroxides and their precursors as dual anti-amyloid and antioxidant active compounds, *European Journal of Medicinal Chemistry* 46 (2011) 1348–1355.
- [11] I.K. Mohan, M. Kahn, S. Wisel, K. Selvendiran, A. Sridhar, C.A. Carnes, B. Bognár, T. Kálai, K. Hideg, P. Kuppusamy, Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction, *Heart and Circulatory Physiology – American Journal of Physiology* 296 (2009) 140–151.
- [12] T. Kálai, M. Balog, A. Szabó, G. Gulyás, J. Jekó, B. Sümegi, K. Hideg, New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-Car-boxamidobenzimidazole-2-ylpyrrolidine and –tetrahydropyridine nitroxides and their precursors, *Journal of Medicinal Chemistry* 52 (2009) 1619–1629.
- [13] T. Kálai, G. Mughes, G. Roy, H. Sies, Z. Berente, K. Hideg, Combining benzo[d]isoxazoles with sterically hindered alicyclic amines and nitroxides: enhanced activity as glutathione peroxidase mimics, *Organic & Biomolecular Chemistry* 3 (2005) 3564–3569.
- [14] D. Thomae, G. Kirsch, P. Seck, Synthesis of selenophene analogues of the tacrine series: comparison of classical route and microwave irradiation, *Synthesis* 40 (2008) 1600–1606.
- [15] K. Hideg, H.O. Hankovszky, L. Lex, Gy. Kulcsár, Nitroxyls; VI. Synthesis and reactions of 3-Hydroxymethyl-2,2,5,5-tetramethyl-2,5-dihydropyrrole-1-oxyl and 3-formyl derivatives, *Synthesis* 12 (1980) 911–914.
- [16] J. Csekő, H.O. Hankovszky, K. Hideg, Synthesis of novel, highly reactive 1-oxyl-2,2,6,6-tetramethyl-1,2,5,6-tetrahydropyridine derivatives, *Canadian Journal of Chemistry* 63 (1985) 940–943.
- [17] P.W. Elsinhorst, C.M.G. Tanarro, M. Gütschow, Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase, *Journal of Medicinal Chemistry* 49 (2006) 7540–7544.
- [18] H.O. Hankovszky, K. Hideg, L. Lex, Nitroxyls VII. Synthesis and reactions of highly reactive 1-Oxyl-2,2,5,5-tetramethyl-2,5-dihydropyrrole-3-ylmethyl sulfonates, *Synthesis* 12 (1980) 914–916.
- [19] K. Hideg, H.O. Hankovszky, J. Tigyi, Nitroxides, I. Sulfonic esters of 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl and their reaction with nucleophilic reactants, *Acta Chimica Academiae Scientiarum Hungaricae* 92 (1977) 85–87.
- [20] T. Kálai, W.L. Hubbell, K. Hideg, Click reactions with nitroxides, *Synthesis* 41 (2009) 1336–1341.
- [21] T. Kálai, M. Khan, M. Balog, K.V. Kutala, P. Kuppusamy, K. Hideg, Structure-activity studies on the protection of trimetazidine derivatives modified with nitroxides and their precursor from myocardial ischemia-reperfusion injury, *Bioorganic & Medicinal Chemistry* 14 (2006) 5510–5516.
- [22] C. Rios, J. Ega, J. Marco-Contelles, R. León, A. Samadi, I. Iriepa, I. Moraleda, E. Gálvez, A.G. Garcia, M.G. López, M. Villaroya, A. Romero, Synthesis inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivative, *Journal of Medicinal Chemistry* 53 (2010) 5129–5143.
- [23] R.M. Dupre, A. Rassat, P. Rey, Nitroxides. XVIII. Pyrrolidine free radicals, *Bulletin de la Société Chimique de France* (1965) 3643–3644.
- [24] M.C. Krishna, W. Degraff, H.O. Hankovszky, P.C. Sár, T. Kálai, J. Jekó, A. Russo, J.B. Mitchell, K. Hideg, Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage, *Journal of Medicinal Chemistry* 41 (1998) 3477–3492.
- [25] H. Zhao, J. Joseph, H. Zhang, H. Karoui, B. Kalyanaram, Synthesis and biochemical applications of a solid cyclic nitroxide spin trap: a relatively superior trap for detecting superoxide anions and glutathyl radicals, *Free Radical Biology & Medicine* 31 (2001) 599–606.
- [26] C. Guarnieri, C. Muscari, Anti oxy-radical properties of trimetazidine, *Research Communications in Chemical Pathology and Pharmacology* 64 (1989) 215–225.
- [27] J.P. Blinco, J.L. Hodgson, B.J. Morrow, J.R. Walker, G.D. Will, M.L. Coote, S.E. Bottle, Experimental and theoretical studies of the redox potentials of cyclic nitroxides, *Journal of Organic Chemistry* 73 (2008) 6763–6771.
- [28] V. Kadlick, C. Sicard-Roselli, T.A. Mattioli, M. Kodicek, C. Houée-Levin, One-electron oxidation of β-amyloid peptide: sequence modulation of reactivity, *Free Radical Biology & Medicine* 37 (2004) 881–891.
- [29] S. Dhitavat, D. Ortiz, E. Rogers, E. Rivera, T.B. Shea, Folate, vitamin E and acetyl-L-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid-beta, *Brain Research* 1061 (2005) 114–117.
- [30] R. Sultana, A. Ravagna, H. Mohammad-Abdul, V. Calabrese, D.A. Butterfield, Ferrulic acid ethyl ester protects neurons against amyloid beta-peptide(1–42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity, *Journal of Neurochemistry* 92 (2005) 749–758.
- [31] I. Maezawa, H.S. Hong, R. Liu, C.Y. Wu, R.H. Cheng, M.P. Kung, H.F. Kung, K.S. Lam, S. Oddo, F.M. Laferla, L.W. Jin, Congo red and thioflavin-T analogs detect Aβ oligomers, *Journal of Neurochemistry* 104 (2008) 457–468.
- [32] J. Petrlova, T. Kálai, I. Maezawa, R. Altman, G. Harishchandra, H.S. Hong, D.A. Bricarello, A.N. Parikh, G.A. Lorigan, L.W. Jin, K. Hideg, J.C. Voss, The influence of spin-labeled fluorene compounds on the assembly and toxicity of the Aβ peptide, *PLoS One* 7 (2012) e35443.
- [33] B.W. Wilson, J.D. Henderson, Determination of cholinesterase in blood and tissue, *Current Protocols in Toxicology* 34 (2007) 12.13.1–12.13.16.